The article you requested is

Switching Drug Class After Initial SSRI Failure

J Clin Psychiatry 1997;58:326-326 [letter]

Letter to the Editor

Sir: The report by Joffe et al. underscores an important issue for the practicing psychiatrist, namely, the appropriate next step for the nonresponder to a serotonin selective reuptake inhibitor (SSRI) antidepressant. Their data from an open-label, non-placebo-controlled database review showed that 51% of patients responded to a second SSRI after experiencing lack of efficacy with their initial SSRI. This response represents an important question to be assessed in controlled trials, and the authors acknowledge that the lack of a placebo-controlled design limits their conclusions.